PlainRecalls
FDA Drug Low Class III Terminated

bupPROPion HCL Extended-Release Tablets, USP (XL) 300 mg, 500-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC: 0378-2009-05

Reported: January 31, 2018 Initiated: November 3, 2017 #D-0230-2018

Product Description

bupPROPion HCL Extended-Release Tablets, USP (XL) 300 mg, 500-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC: 0378-2009-05

Reason for Recall

Failed Impurities/Degradation Specifications: Mylan Pharmaceuticals Inc. is conducting a voluntary recall due to related out of specification compound results obtained during routine stability testing.

Details

Units Affected
1,414/500 count bottles
Distribution
Product was distributed nationwide in the USA
Location
Morgantown, WV

Frequently Asked Questions

What product was recalled?
bupPROPion HCL Extended-Release Tablets, USP (XL) 300 mg, 500-count bottle, Rx only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. NDC: 0378-2009-05. Recalled by Mylan Pharmaceuticals Inc.. Units affected: 1,414/500 count bottles.
Why was this product recalled?
Failed Impurities/Degradation Specifications: Mylan Pharmaceuticals Inc. is conducting a voluntary recall due to related out of specification compound results obtained during routine stability testing.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 31, 2018. Severity: Low. Recall number: D-0230-2018.